Article Per Year (5 Year)
p-Index From 2021 - 2026
1.836
P-Index
This Author published in this journals
All Journal Jurnal Ilmu Farmasi dan Farmasi Klinik (Journal of Pharmaceutical Science and Clinical Pharmacy) Molecular and Cellular Biomedical Sciences (MCBS) Manuju : Malahayati Nursing Journal Jurnal Mandala Pharmacon Indonesia International Journal of Applied Technology Research TRILOGI: Jurnal Ilmu Teknologi, Kesehatan, dan Humaniora International Journal of Economics (IJEC) Eduvest - Journal of Universal Studies Riwayat: Educational Journal of History and Humanities Jurnal Informatika: Jurnal Pengembangan IT Folia Medica Indonesiana
Yulistiani Yulistiani, Yulistiani
Mahasiswa Jurusan Perencanaan Wilayah dan Kota, Fakultas Teknik, Universitas Diponegoro
Aerospace Engineering Humanities Automotive Engineering Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Computer Science & IT Control & Systems Engineering Dentistry Economics, Econometrics & Finance Education Electrical & Electronics Engineering Energy Engineering Health Professions Immunology & microbiology Industrial & Manufacturing Engineering Materials Science & Nanotechnology Mechanical Engineering Medicine & Pharmacology Neuroscience Nursing Physics Public Health Social Sciences Other

Published : 28 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 28 Documents
Search

 1   2   3 
Effects of methyldopa on vegf levels as proangiogenic factor in severe pre-eclampsia at haji hospital, surabaya Juwita, Dina Ratna; Yulistiani, Yulistiani; M, Eddy Zarkaty
Folia Medica Indonesiana Vol. 53, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Methyldopa is the main antihypertensive drug widely used in pregnant women with hypertensive disorder. It lowers blood pressure in pre-eclampsia by affecting a2-adrenoreceptors in central nervous system. However, it also decreases the production of proangio-genic factors that involved in the pathophysiology of hypertension in pre-eclampsia. Vascular Endothelial Growth Factor (VEGF) is one of proangiogenic and mitogenic factor that important for vasodilatation. VEGF is produced by the placenta and affected after treatment with methyldopa. The aim of this study was to analyze the effects of methyldopa on VEGF maternal circulating level as a proangiogenic factor in severe pre-eclampsia patients who were hospitalized at Obstetrics and Gynecology Department, Haji Hospital, Surabaya. This study was performed by cohort prospective observational method on August to October 2016.The data was assessed at before and 48 hours after methyldopa therapy. The study was approved by the ethical committee of Haji Hospital, Surabaya. There were 19 patients with severe pre-eclampsia who met inclusive criteria. The results showed that levels of VEGF before and 48 hours after 250 mg methyldopa therapy were 1178.37(281.97-3567.28) pg/mL and 1055.17 (129.79-4272.66) pg/mL, respectively. VEGF levels in severe pre-eclampsia patients were 1194.29 (175.68-3432.01) pg/mL at before treatment and 510.66 (214.34-1236.16) pg/mL after treatment with methyldopa 500 mg therapy. In conclusion, methyldopa could decrease VEGF level on severe pre-eclampsia patients, with a decrease of 10% at the dose of 250 mg and 57% at the dose of 500 mg.
Phosphatidylglycerol study as fetal lung maturation parameter after dexamethasone administration for women at risk of preterm birth Rahmadani, Rizal Umar; Sulistyono, Agus; Yulistiani, Yulistiani; Yahya, Muhammad
Folia Medica Indonesiana Vol. 52, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Phosphatidylglycerol is an important indicator of fetal lung maturation, which plays a role in stabilizing surfactant lipoprotein complex. Corticosteroid antenatal can stimulate the synthesis of pulmonary surfactant in infants with preterm birth. The objective of this study is to examine the phosphatidylglycerol levels as fetal lung maturation parameter after dexamethasone administration in women with preterm birth compared to L/S ratio parameter. This study was prospective longitudinal (cohort). The samples were pregnant women with preterm birth risk at 28-34 weeks gestation getting the therapy of antenatal dexamethasone 6 mg IM every 12 hours given 4 times in 48 hours. The samples were 17 patients. Determination of L/S ratio and PG levels was performed by ELISA. The study was conducted from May - November 2015 and reviewed to obtain ethics eligibility permit by the research ethic committees of Dr. Soetomo General Hospital. The results show that the mean value of L/S ratio is 2.28 with a range of 1.35 to 9.06 and the mean of PG level is 1.17 with a range from 0 to 3.79. L/S ratio and PG show no significant relationship between the two of them. Increased levels of PG on the gestational age of 28-32 weeks have not demonstrated clinically significant changes yet. The highest PG level occurs in the gestational age of 32-34 weeks.
Children with Standard Risk Acute Lymphoblastic Leukemia in Induction And Consolidation Phase Amarullah, Adinugraha; Hasmono, Didik; Ugrasena, IGD; Yulistiani, Yulistiani
Folia Medica Indonesiana Vol. 54, No. 1
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Prednisone has an important role in the therapy of patient with standard risk ALL. Patients with standard risk ALL receiving high dose prednisone as therapy and supraphysiology dose of prednisone are expected to cause suppression in HPA-axis (Hypothalamic Pituitary Adrenal axis). This suppression could reduce immune system in children with ALL and increase infection risk because reduction of cortisol level. In Indonesia, we did not find study about the incident of adrenal suppression after high dose prednisone therapy, especially in induction to consolidation phase ALL patient. The aim of this study was to analyze adrenal suppression after high dose prednisone therapy on children with standard risk acute lymphoblastic leukemia in induction and consolidation phase. This study has received a certificate of Ethical Clearance No. 588/Panke.KKE/X/2016, a longitudinal observational, prospective, non-randomized trial involving children with ALL who received prednisone for 49 days during the induction phase. We collected and compared laboratory result of cortisol level in children with ALL and received prednisone therapy during induction to consolidation phase. Sample was taken at week 0,4,5,6,7,8,10,12 in the course of ALL chemotheraphy Indonesian protocol year 2013. Serum was examined using methods CLIA ADVIA Centaur® XP. Between June 2016 – January 2017, 13 patients (8 males, 5 females) were included in this study. Decrease of cortisol level after prednisone therapy occured in week-10 as much as 53% compared with week-0 (p=0.027). Cortisol level increased 64% of week-12 compared with week-10 (p=0.003). In conclusion, high dose prednisone is not significant to causing adrenal suppression in induction phase of ALL patients, and the reducing cortisol level is reversible.
Analysis of Methyldopa Therapy on sFlt-1 Antiangiogenic Levels in Patients with Severe Preeclampsia Herwati, Teri Wina; Yulistiani, Yulistiani; M, Eddy Zarkaty
Folia Medica Indonesiana Vol. 54, No. 1
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Methyldopa is the first-line drugs to treat hypertension in pregnancy. It can decrease blood pressure in preeclampsia by affecting a2-adrenoreceptors in central nervous system. However, it could also act by decreasing production of sFlt-1 antiangiogenic protein levels involved in the pathophysiology of hypertention in preeclampsia. The purpose of this study was to analyze methyldopa therapy on sFlt-1 antiangiogenic levels in the plasma of pregnant women with severe preeclampsia at the Obstetric Departement, Haji Hospital, Surabaya. This was a prospective study with observational cross-section study design. The sFlt-1 angiogenic levels were observed before and after (48 hours) methyldopa administration in severe preeclampsia patient with or without complications in the period of August to October 2016. Patient received methyldopa 250 mg or 500 mg, three times a day for clinical indications according a standard protocol. The study was approved by the ethical committee of Haji Hospital, Surabaya. There were 19 patients with preeclampsia who met the inclusion criteria, showed a decrease in the levels of sFlt-1 before and 48 hours after methyldopa therapy. Levels of sFlt-1 before methyldopa therapy in a dose of 250 mg was 10.15±10.00 (2.55-34.70) ng/ml and after therapy 8,37±9,20 (0.72-9.20) ng/ml, with a percentage decrease 17.54%. sFlt-1 levels before methyldopa therapy in a dose of 500 mg was 8.05±7.07 (2.55-20.76) ng/ml, after therapy 4.50±2.90 (2.19-9.95) ng/ml, with a percentage decrease 44.16%. Methyldopa therapy could decrease sFlt-1 levels of antiangiogenic factor in patients with severe preeclampsia.
Methotrexate use is safe in children with acute lymphoblastic leukemia Utomo, Febriansyah Nur; Yulistiani, Yulistiani; Zairina, Nun; Permono, Bambang
Folia Medica Indonesiana Vol. 53, No. 2
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Monitoring level of methotrexate is not only aimed at monitoring effectiveness, but also safety aspects of the administration of high-dose methotrexate because the use of high-dose methotrexate is one of the problems associated with toxicity in various organs. In the use of high-dose methotrexate, measurement of methotrexate is important to identify patients with a high risk of toxicity, particularly nephrotoxicity as well as for dosing guidelines for leucovorin therapy. The aim of this study was to analyze the safety of high-dose methotrexate on kidney function during chemotherapy consolidation phase in children with acute lymphoblastic leukemia. This was a longitudinal, observational prospective study conducted to determine the safety profile of high-dose methotrexate on kidney function during chemotherapy consolidation phase in children with acute lymphoblastic leukemia. Patients who met the inclusion criteria were given high-dose methotrexate according to the 2013 Indonesian ALL Chemotherapy Protocol. Measurement of methotrexate level and kidney function was done 3 times on each cycle of chemotherapy consolidation phase. Measurements were made on the 0, 24 and 48 hours after the first drop of high-dose methotrexate. This study had been reviewed by Ethics Committee of Dr. Soetomo Hospital Surabaya. There were 12 patients who met inclusion criteria and 6 patients among them had finished their chemotherapy consolidation phase completely. There was no significant change in kidney function after the administration of high-dose methotrexate compared to baseline (p>0.05) and there was no significant correlation between serum level of methotrexate versus creatinine clearance. In conclusion, methotrexate was safe to use in children with acute lymphoblastic leukemia.
Analysis of High Dose and Long-Term Prednisone Therapy on Trap 5B Level Change in Children with Steroid Sensitive Nephrotic Syndrome Setyani, Dessy Surya; Qibtiyah, Mariyatul; Asmaningsih, Ninik; Yulistiani, Yulistiani
Folia Medica Indonesiana Vol. 54, No. 2
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Nephrotic syndrome is a condition which is characterized by protein leakage from the blood to the urine through glomeruli. It leads to hypoproteinemia and generalised oedema. Patients with nephrotic syndrome need high dose and long term glucocorticoid such as prednisone. High dose and long term glucocorticoid can increase bone resorption. Biological marker is a valuable tool to evaluate efficacy of therapy. TRAP 5B is a sensitive biological marker for bone resorption because it reflects the number of osteoclasts. TRAP 5B is not affected by renal dysfunction and food. It also has a low diurnal variation than other bone resorption marker. The aim of this study was to analyze the changes of TRAP 5B levels at induction and alternate phase in children with steroid sensitive nephrotic syndrome. This observational prospective study was conducted from May to October 2016. Venous blood samples obtained at 08.00-10.00 am. TRAP5B levels were measured before and after induction phase and after alternate phase using ELISA. Fifteen patients were included in this study (60% boys). Majority of their age was 6 - <12 years and 40% were dependent steroid NS. TRAP 5B serum levels in induction phase increased by 37.41%±56.22%. In alternate phase, TRAP 5B serum levels increased by 28.75%±66.55% compared to the induction phase. However, the level change of both phases were not significant. As a conclusion, TRAP 5B levels increased in induction and alternate phase after high dose and long-term prednisone treatment in nephrotic syndrome.
Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia Widya, Reta Anggraeni; Nugroho, Susanto; Winarsih, Sri; Yulistiani, Yulistiani
Folia Medica Indonesiana Vol. 55, No. 1
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Cytotoxic chemotherapy suppresses the hematopoietic system, and the most serious hematologic toxicity is neutropenia. This can decrease a risk of infection that causes delays in treatment and reduction of dose intensity, which reduces therapeutic outcome. Filgrastim is used to increase neutrophils level whose therapeutic effect is unknown. The effectiveness of filgrastim is based on the ANC level pre- and post-therapy. This study aimed to analyze the use of filgrastim on ANC level changes in acute leukemia children with neutropenia, and to analyze the patient that achieve ANC level's targeted therapy = 1000 cell/mm3. A prospective observational study with a longitudinal design was conducted from June to October 2016. The inclusion criteria of the study were patients who diagnosed acute leukemia with neutropenia and received filgrastim 10 µg/kgBW for 3, 4, 5 days. Patients' ANC levels were measured before and after filgrastim therapy. This study has been approved its ethical clearance by Dr. Saiful Anwar Hospital, Malang. Data were obtained on the basis of neutropenic episodes, followed by 7 episodes of obtaining filgrastim for 3 days, 1 episode of obtaining filgrastim for 4 days, and 7 episodes of obtaining filgrastim for 5 days. Thus, it consists of 15 episodes. In 3 days, ANC levels increased by 9.5 fold from 381.3 ± 91.8 cell/mm3 to 3984.9 ± 426.8 cell/mm3, but in 5 days, ANC levels decreased by 0.9 fold from 200.9 cell/mm3 ± 98.2 to 189.7 ± 14.2 cell/mm3. Filgrastim was able to increased the ANC levels around nine fold for 3 days of theraphy. There were 53% neutropenia patients who achieved the goal of therapy. Filgrastim therapy with dose 10 µg/kgBW for 3 to 5 days has been able to reach the therapeutic target of 53% in acute leukemia children with neutropenia. The increased levels of ANC maximum was reached on the third day with increased levels of 9.5 fold.
Review : Alirocumab dan Evolocumab sebagai Agen Penurun Lipid Baru Alfatihah, Humaira Izka; Yulistiani, Yulistiani
Jurnal Mandala Pharmacon Indonesia Vol. 11 No. 2 (2025): Jurnal Mandala Pharmacon Indonesia 
Publisher : Program Studi Farmasi Universitas Mandala Waluya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35311/jmpi.v11i2.849

Abstract

Angka kematian yang disebabkan oleh penyakit kardiovaskular di seluruh dunia masih relatif tinggi. Salah satu faktor risikonya adalah LDL-C (low density lipoprotein cholesterol), di mana memodifikasi faktor ini diharapkan dapat mencegah kejadian kardiovaskular. Penghambat PCSK9 (proprotein convertase subtilisin/kexin type 9) adalah agen penurun lipid baru dengan mekanisme yang mempertahankan reseptor LDL-C di dalam darah. Untuk meninjau penelitian terbaru mengenai efektivitas dan keamanan agen penghambat PCSK9, Alirocumab dan Evolocumab, serta potensinya dalam menurunkan kadar lipid. Pencarian literatur menggunakan database elektronik PubMed dengan kata kunci ‘Alirocumab’, ‘Evolocumab’, ‘LDL-C’, ‘Kardiovaskular’, ‘Dislipidemia’, dengan kriteria 5 tahun terakhir dan teks lengkap dalam bahasa Inggris. Dari 12 artikel yang telah disaring kemudian akan direview. Nilai LDL-C menurun secara signifikan rata-rata 53% (11%-72%) dengan efek samping yang ringan, seperti nasofaringitis, diare, dan reaksi tempat suntikan. Alirocumab dan Evolocumab disuntikkan secara subkutan setiap 2 minggu atau 4 minggu. Penghambat PCSK9 berbasis antibodi monoklonal dapat menjadi alternatif untuk pencegahan kardiovaskular berisiko tinggi bagi pasien yang memiliki riwayat dosis statin yang dapat ditoleransi atau pasien yang tidak toleran terhadap statin.
Co-Authors A.A. Ketut Agung Cahyawan W Agus Sulistyono Alfatihah, Humaira Izka Amarullah, Adinugraha Amir, Nur Rezky Rutami Anggraini, Dian Septi Asmaningsih, Ninik Assaidiqi, M. Irfan Bagus PP Suryana, Bagus PP Bambang Permono Berliana, Dini Budi Suprapti Darto Saharso Desantika Wuryana, Desantika Didik Hasmono Dwiyatna, Surya Ekanita Desiani Erwin Saputra Siregar Gustaji, F Herni Setyawati Herwati, Teri Wina Juwita, Dina Ratna Karisma, R F M, Eddy Zarkaty Mamo, Hendriette Irene Mariyatul Qibtiyah Markus, Unedo H Melawati Olevianingrum, Melawati Mellyani, Netty Purnama Sari Mia Ratwita Andarsini Muhammad Shohib, Muhammad Muhammad Yahya Muzayyanah, Binti Nazori, Nazori Nisriyati Fiddina Nun Zairina, Nun Nur ‘Azah Oktavia, Nur Permanasari, Ayu Ratna Purwiningtyas, Mida Rahmadani, Rizal Umar Rana, Rana Rismayanti, Levana Rusmiyati, Melly Santi, Bayu Dharma Setyani, Dessy Surya Simbolon, Octaviana Soedarsono Soedarsono Sri Winarsih Styawati, Styawati Suharjono, Suharjono Susanto Nugroho Susilo, Dwi Hari Ugrasena, I DG Ugrasena, IGD UMI FATMAWATI Utomo, Febriansyah Nur WAHYU WIBISONO Warni, Asri Indahning Widya, Reta Anggraeni Widya, Reta Anggraeni Wisudani, Nuraida